Trials Sponsors Conditions Drugs Pricing

Conditions

Colo-rectal Cancer

Outcome Measures

Primary Outcomes (1)

Progression-Free Survival (PFS)
From the date of first administration of study treatment to the date of first documented tumor progression or death from any cause, whichever occurs first.
From the date of first administration of study treatment to the date of first documented tumor progression or death from any cause, whichever occurs first，assessed up to 5 years.

Study Arms (1)

radiotherapy and immunotherapy and fruquintinib

EXPERIMENTAL

Radiation: Personalized ultrafractionated stereotactic adaptive radiotherapyDrug: ImmunotherapyDrug: Target Therapy

Interventions

Personalized ultrafractionated stereotactic adaptive radiotherapyRadiation

Radiotherapy will be delivered at 25-50 Gy in 5 fractions, including dose schedules of 40 Gy in 5 fractions and 50 Gy in 5 fractions

radiotherapy and immunotherapy and fruquintinib

ImmunotherapyDrug

Finotonlimab 200 mg administered once every 21 days; each treatment cycle is 21 days

radiotherapy and immunotherapy and fruquintinib

Eligibility Criteria

Age18 Years - 75 Years

Sexall

Healthy VolunteersNo

Age GroupsAdult (18-64), Older Adult (65+)

You may qualify if:

Has fully understood the study and voluntarily signed the informed consent form.
Aged 18-75 years, with no restriction on sex.

Sponsors & Collaborators

West China Hospital
Otherlead

MeSH Terms

Conditions

Colonic Neoplasms

Interventions

Immunotherapy

Condition Hierarchy (Ancestors)

Colorectal NeoplasmsIntestinal NeoplasmsGastrointestinal NeoplasmsDigestive System NeoplasmsNeoplasms by SiteNeoplasmsDigestive System DiseasesGastrointestinal DiseasesColonic DiseasesIntestinal Diseases

Intervention Hierarchy (Ancestors)

Immunomodulation

Central Study Contacts

shu pei

CONTACT

+86 15881109332 shupei385@gmail.com

Study Design

Study Type: interventional
Phase: phase 2
Allocation: NA
Masking: NONE
Purpose: TREATMENT
Intervention Model: SINGLE GROUP
Sponsor Type: OTHER
Responsible Party: PRINCIPAL INVESTIGATOR
PI Title: Clinical Professor

Study Record Dates

First Submitted

September 25, 2026

First Posted

October 29, 2026

Study Start

October 9, 2026

Estimated (date passed)

This estimate has passed. The registry has not confirmed an actual date for this milestone.

Primary Completion

October 1, 2028

You may not qualify if:

Receipt of any investigational drug treatment within 4 weeks before the first administration of study treatment.
Concurrent participation in another clinical study, unless it is an observational (non-interventional) study or the follow-up phase of an interventional clinical study.
Receipt of brachytherapy, such as radioactive seed implantation, within 60 days before the first dose.
Uncontrolled serious illness that, in the investigator's opinion, may impair the participant's ability to receive protocol-specified treatment, including severe cardiac disease, cerebrovascular disease, uncontrolled diabetes mellitus, uncontrolled hypertension, uncontrolled infection, or active peptic ulcer disease.
Active, known, or suspected autoimmune disease, including but not limited to uveitis, enteritis, hepatitis, hypophysitis, nephritis, vasculitis, hyperthyroidism, hypothyroidism, and asthma requiring bronchodilator therapy. Participants with hypothyroidism requiring hormone replacement therapy and those with skin conditions not requiring systemic treatment, such as vitiligo, psoriasis, or alopecia, may be enrolled.
Active tuberculosis infection. Participants with active pulmonary tuberculosis within 1 year will be excluded, even if treated. Participants with a history of active pulmonary tuberculosis more than 1 year before enrollment will also be excluded unless they can demonstrate completion of standard anti-tuberculosis therapy.
Requirement for long-term systemic corticosteroid therapy at a dose equivalent to \>10 mg/day of prednisone, or any other form of immunosuppressive therapy. Participants receiving inhaled or topical corticosteroids may be enrolled.
Uncontrolled cardiac disease, including New York Heart Association (NYHA) class II or higher heart failure; unstable angina; myocardial infarction within 1 year; clinically significant supraventricular or ventricular arrhythmias requiring treatment or intervention; dementia, altered mental status, or any psychiatric disorder that may impair comprehension, provision of informed consent, or completion of study questionnaires.
History of another malignancy within 5 years before enrollment, except for adequately treated basal cell carcinoma or squamous cell carcinoma of the skin, localized prostate cancer after curative surgery, or ductal carcinoma in situ of the breast after curative treatment.
Active gastric or duodenal ulcer, ulcerative colitis, or other gastrointestinal disease; unresected tumors with active bleeding; or any other condition considered by the investigator to pose a risk of gastrointestinal bleeding or perforation. Participants with prior gastrointestinal perforation or gastrointestinal fistula who have not recovered after surgery will be excluded.
Positive hepatitis C virus (HCV) antibody or human immunodeficiency virus (HIV) antibody.
Active infection requiring systemic treatment.
Contraindication to penpulimab or fruquintinib, including a history of allergy or hypersensitivity to any component of either drug.
Contraindication to radiotherapy, such as prior adequate-dose radiotherapy to the same site, severe radiation injury to the skin or local tissues/organs, or inability to tolerate re-irradiation.
Any other condition that, in the investigator's judgment, makes the participant unsuitable for enrollment.

Personalized Ultrafractionated Stereotactic Adaptive Radiotherapy Combined With Penpulimab and Fruquintinib for Advanced Colorectal Cancer

Brief Summary

Registry Overview

Trial Relationships

Study Timeline

First Submitted

Study Start

First Posted

Primary Completion

Study Completion

Conditions

Outcome Measures

Primary Outcomes (1)

Study Arms (1)

radiotherapy and immunotherapy and fruquintinib

Interventions

Eligibility Criteria

You may qualify if:

Sponsors & Collaborators

MeSH Terms

Conditions

Interventions

Condition Hierarchy (Ancestors)

Intervention Hierarchy (Ancestors)

Central Study Contacts

Study Design

Study Record Dates

You may not qualify if:

Source record

Documents

Brief Summary

Registry Overview

Trial Relationships

Related Scientific Literature

Study Timeline

First Submitted

Study Start

First Posted

Primary Completion

Study Completion

Conditions

Outcome Measures

Primary Outcomes (1)

Study Arms (1)

radiotherapy and immunotherapy and fruquintinib

Interventions

Eligibility Criteria

You may qualify if:

Sponsors & Collaborators

MeSH Terms

Conditions

Interventions

Condition Hierarchy (Ancestors)

Intervention Hierarchy (Ancestors)

Central Study Contacts

Study Design

Study Record Dates

You may not qualify if:

Source record

Documents